{"name":"Dermata Therapeutics","slug":"dermata","ticker":"DRMA","exchange":"NASDAQ","domain":"dermatatherapeutics.com","description":"Dermata Therapeutics is a biopharmaceutical company focused on developing innovative treatments for dermatological diseases. The company's pipeline includes several promising candidates, including DRM01 and DRM04. Dermata Therapeutics is a relatively small player in the dermatology market, but its unique approach and strong R&D capabilities make it an attractive investment opportunity.","hq":"San Diego, CA","founded":0,"employees":"","ceo":"Gerald T. Proehl","sector":"Dermatology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$20M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2031-06-01","label":"DRM01 patent cliff ($10.0M at risk)","drug":"DRM01","type":"patent_expiry","sentiment":"negative"},{"date":"2034-06-01","label":"DRM04 patent cliff ($20.0M at risk)","drug":"DRM04","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Dermata Therapeutics Announces FDA Clearance of IND for DRM01","summary":"Dermata Therapeutics announced that the FDA has cleared the Investigational New Drug (IND) application for DRM01, a novel treatment for psoriasis.","drugName":"DRM01","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Dermata Therapeutics Reports Third Quarter 2023 Financial Results","summary":"Dermata Therapeutics reported its third quarter 2023 financial results, with revenue of $1.2 million and a net loss of $12.1 million.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE85RS1xT1M5dW16XzFTUXdNTkJDdzc0bF9WRm1SWFNRMlBrVGRRZnJCaFd2UEpvZTFMMXBCMk0tYm8zLU96MDBLX1VvcWcxSnZpRHhjZDd6T1p3V29DS19Zb3NmbFpGTVNWcG9ROWp5Q0RwWHZRRi1sUENZZknSAXxBVV95cUxPOUUtcU9TOXVtel8xU1F3TU5CQ3c3NGxfVkZtUlhTUTJQa1RkUWZyQmhXdlBKb2UxTDFwQjJNLWJvMy1PejAwS19Vb3FnMUp2aUR4Y2Q3ek9ad1dvQ0tfWW9zZmxaRk1TVnBvUTlqeUNEcFh2UUYtbFBDWWZJ?oc=5","date":"2026-03-27","type":"pipeline","source":"AlphaStreet","summary":"Dermata Therapeutics 2025 Financial Update - AlphaStreet","headline":"Dermata Therapeutics 2025 Financial Update","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQS2VKS21XU2tnTkRPRFNiQ3R0aE1kR1U4RllzZE5uOVFwWW1yY2xEaHB6UUkzMUdGQmlQRVk4dVlWeTN0ZnFnak5hd2hPc3liTUNhak5XTWFqN1NNUjFwTm1FYU9OS3Z3TGFyQzV1bTFqZGVOUlhyU2QyM3VaNkhhRmN1T2ZiNjNXNWNPZmdvNzZhTFE3M1hpUi1MWlMtMVJ6NGdZNUJralFqOFg4d1hlanBpTTM?oc=5","date":"2026-02-20","type":"pipeline","source":"Benzinga","summary":"12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga","headline":"12 Health Care Stocks Moving In Friday's Pre-Market Session","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxQVTlhUWk4MDZGcEt5WEprU0VYLVMxc2tEdFBSMWhoU0RjUWNvUXNPdW5hQWhqYWxVc054enIySEg4X3NlTDJjUG9zU2xDcWtBaktvYkYxVC1LekpXYWNjY2xHc01TV1pyaDRmN0xWSURITlBIeXVoci1XRV9Iamt5cjEyaWVidw?oc=5","date":"2026-02-11","type":"pipeline","source":"Moomoo","summary":"This Stock Could Go 10X UP. - Moomoo","headline":"This Stock Could Go 10X UP.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxQZy00SE9iTkd2emdtaXZ5OG1SWGM5NGxxdkw2NG9qMTJqajc0VHVLZkNsSEhiQm50cGJwWVNqN2E1aFhfWm5NRE5UbGZBWVJkSG5Ea2JRRTRHSGZOX25GVEZoY0tQZzkzQXlITEtwcE5oX3lGRGpHSTZLcHJMT19RTGU5T0lfcHZnOWlld2tjM3VRd09XWkRVUXA3aDN4cFo1YVNIYjY3QWFhcGhXWHB4SVN3UHJZeEhsc3JDdVoybE11OG1zRnRNRk1QczdCSDNjeDZkNF94UGpNcDQzZHp2S3ByLXF0SW9kVnZ5QQ?oc=5","date":"2025-10-07","type":"regulatory","source":"Benzinga","summary":"Why Telomir Pharmaceuticals Shares Are Trading Higher By 31%; Here Are 20 Stocks Moving Premarket - Benzinga","headline":"Why Telomir Pharmaceuticals Shares Are Trading Higher By 31%; Here Are 20 Stocks Moving Premarket","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiV0FVX3lxTE5UQ2lQUkltUFpIR0VMVGl4NHlwR2RxVk4teW5lZjQwaF9JczYtMTZoVnVOajNBeVZoOGptcmhFOEFNb1NJNldyWWdXQ3Y2ZmFHYXpxNlo4SQ?oc=5","date":"2025-09-25","type":"pipeline","source":"Stock Titan","summary":"DRMA SEC Filings - Dermata Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan","headline":"DRMA SEC Filings - Dermata Therapeutics Inc 10-K, 10-Q, 8-K Forms","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxOOHZ3NUpqVFB3ZnpuWGVKN0NkQldyRDNfZW1JSWt6UVdTRlZOVlFKMzJ6amhsU295VjljQ0hlYjNVTlJxQ0NRVGs0Nk1UdTl3TnhkS0x3SFdOV0lDNmF2aXY4d1h2SlZuSnE3Wm1oMlcyYjJ3UWI2ZWVQNjBzaUlOcVRBOGxHV21ybUk0SHBGXy12bFcwamJ0RTBiRGNNWTBaVmk5Wjd4U2F0aER6cURETDN6dURyWHgzWEpSd3NsczFsdHNwU04w?oc=5","date":"2025-07-30","type":"pipeline","source":"Investing.com","summary":"Dermata Therapeutics to implement 1-for-10 reverse stock split on August 1 - Investing.com","headline":"Dermata Therapeutics to implement 1-for-10 reverse stock split on August 1","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFB2eTNvOTR1VU5uZFgzdzl0aWZsWmZnWW9sa3VPMHBGUW1jSmwtWWlVVTVZLVNYTXBUenBqVWltRzNpRkQ1aUE4eVRkaENEYktCRF9N?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"DRMA Stock Price, News & Analysis - Stock Titan","headline":"DRMA Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9AFBVV95cUxOWVM1aEFBUmdEREZSd3h6MEV5WlE3N0VsaWxjOTlIcHY5U01tT3hXZnFoRkZOMDh5SUxIU1R4SmtuaFYyRUFrNHVvVVpmeXhRQThnS0JTcjZHbGZPcWp4WmJJeW40RHJLbUlTU3J5aDd2RmJiRmJBaGV5THdGVmtfNWpvU1c0UWdJMjFCQkpjWVMtemdyNF9oQWFFNU5wT2xvR2dJWlo3OGlKZG5HenA2NVZZak1EWl9lQWxOODNzYzlLU1c1VzRiT2pkT3J0TFRINlN6ajJtR2MtNWdVV0xDLTFYTHZPbXVMam4zSU5Xcy1ZRTJi?oc=5","date":"2023-05-09","type":"regulatory","source":"proactiveinvestors.com","summary":"Dermata Therapeutics awaits FDA go-ahead for lead candidate DMT310 to enter Phase 3 studies - proactiveinvestors.com","headline":"Dermata Therapeutics awaits FDA go-ahead for lead candidate DMT310 to enter Phase 3 studies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE42NDFsSVdQeHphUmZJR09kQ0ZTb1l3ajJYVXdNbEV2TDhiU0JfaWFNazk1MWRtX1pJcmNsLVQyWU9mZU9qeDBPblNiSDFILVhlVmNvQVBjZTBrZERT?oc=5","date":"2023-04-18","type":"pipeline","source":"TradingView","summary":"DRMA Stock Price and Chart — NASDAQ:DRMA - TradingView","headline":"DRMA Stock Price and Chart — NASDAQ:DRMA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTFBQRDRJQ1VHOER1VFFnQ2NBV0xnMUFvSThqOWF6N3BpbmdYSFBLV1BEQ0dSX3NUMFVlNDNfSnN5Mi1pdEl0MS10ME5jdmF2THNYbGc?oc=5","date":"2022-08-05","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Dermata Therapeutics, Inc. (DRMA) stock price, news, quote and history - Yahoo Finance Singapore","headline":"Dermata Therapeutics, Inc. (DRMA) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9WV0g0d0k3dEJ2MzUxcmNPc3dHbjFSTXJwSzFTdXdiVVMzckd2Q0V1SUZXckJmVHp2b3dVUDl3RkUwLWNwWFAtcFZzRjVZN2wzeDhFbC1tOXotY1JYQWUw?oc=5","date":"2021-11-02","type":"pipeline","source":"ChartMill","summary":"DRMA Stock Price, Quote & Chart | DERMATA THERAPEUTICS INC (NASDAQ:DRMA) - ChartMill","headline":"DRMA Stock Price, Quote & Chart | DERMATA THERAPEUTICS INC (NASDAQ:DRMA)","sentiment":"neutral"}],"patents":[{"drugName":"DRM01","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2031-06-01","territory":"US","annualRevenue":10000000},{"drugName":"DRM04","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":20000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Almirall","Galderma","L'Oréal"],"therapeuticFocus":["Psoriasis","Atopic Dermatitis"],"financials":null,"yahoo":null}